In 1993 , Guangzhou Nanxin Pharmaceutical was established. It was jointly invested by India RANBAXY and Guangzhou Baiyunshan Pharmaceutical Group Qiaoguang Pharmaceutical Co., Ltd. and Hong Kong Enterprise Co., Ltd., and became the first Sino-Indian joint venture in China.
In 1997 , Guangzhou Nanxin Pharmaceutical Co., Ltd. obtained the Chinese pharmaceutical GMP certification. It is the first batch of enterprises that have passed the national GMP certification, with an annual output of 5 million bottles of infusion , 75 million tablets and capsules, and 2 million bottles of children's dry suspension. And 5 million powder needles .
In 2005 , RANBAXY India invested in the “Technology Development Laboratory” ( TDL ) at the Guangzhou Nanxin Plant to accelerate the commissioning of new products. Ranbaxy has already listed 53 registrations in drugs, including 10 kind of "national essential drugs", two separate product pricing, as well as RANBAXY patented products, "noted the complex Huan OD " ( CifranfranOD ).
In 2009 , Hunan Nonferrous Metals Platinum Biopharmaceutical Co., Ltd., a subsidiary of China Minmetals, acquired Guangzhou Nanxin, which brought new opportunities for Nanxin development. With close cooperation with the National Academy of Military Medical Sciences, there will soon be a group of original research and first imitation. The drug is on the market.